Please assess the completion status of the following clinical trial:

Trial Title: Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes mellitus.~* Treated with diet and exercise and a stable, maximally tolerated dose of metformin for at least 3 months prior to screening.~* HbA1c \>=6.5% and \<=9.0%.~* Body Mass Index (BMI) \>=25 kg/m\^2 and \<40 kg/m\^2.~Exclusion Criteria:~* Participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to screening.~* Characteristics contraindicating metformin or glimepiride use.~* Receiving drugs that directly affect gastrointestinal motility.~* Receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy.~* Have used any prescription drug to promote weight loss within 3 months prior to screening.~* Treated for longer than 2 weeks with any of the following medications within 3 months prior to screening: \*insulin; \*thiazolidinediones; \*alpha-glucosidase inhibitors; \*sulfonylurea; \*meglitinides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): None
- Glimepiride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).